Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | AOC1 | P19801 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469127 | 0.84 | TLR8 (0.53) | SCN9ASCN5AKCNH2CDK2TLR8 | |
| SCHEMBL3193118 | 0.82 | TLR8 (0.47) | SCN9ASCN5AKCNH2TLR8HCAR3 | |
| SCHEMBL3186741 | 0.81 | TLR8 (0.46) | TLR8HCAR3 | |
| SCHEMBL13101043 | 0.78 | KDM4E (0.47) | SCN9ASCN5AKCNH2CDK2 | |
| SCHEMBL12497287 | 0.77 | GRM5 (0.35) | SCN5AKCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL13101041 | 0.76 | HRH3 (0.46) | SCN9ASCN5AKCNH2CDK2TLR8 | |
| SCHEMBL13159701 | 0.76 | — | — | |
| SCHEMBL6468910 | 0.75 | FYN (0.51) | SCN9ASCN5AKCNH2CDK2HCAR3 | |
| SCHEMBL3183903 | 0.75 | HCAR3 (0.38) | SCN9ASCN5AKCNH2CDK2HCAR3 | |
| SCHEMBL21827821 | 0.72 | KDM4E (0.46) | SCN9ASCN5AKCNH2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| EP-1654260-A4 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1654260-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005011601-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | SCN9A 666/4885SCN5A 1919/4885KCNH2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.